Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.06.22.20133413: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: All patients provided an informed consent for treatment with off label agents according to the local protocol approved by Hospital Authorities, for data collection and for participation in the study.
IACUC: The study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Regional Ethic Committee (N.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Stata (v.16; StataCorp.) was used for the computation. StataCorpsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect …
SciScore for 10.1101/2020.06.22.20133413: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: All patients provided an informed consent for treatment with off label agents according to the local protocol approved by Hospital Authorities, for data collection and for participation in the study.
IACUC: The study was carried out in accordance with the principles of the Declaration of Helsinki and approved by the Regional Ethic Committee (N.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Stata (v.16; StataCorp.) was used for the computation. StataCorpsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The limitations of this study include the non-randomized design, yet the inclusion of consecutive patients using the same SOC but not treated with tocilizumab or methylprednisolone, and adjustment for the outcome-associated variables, allowed to notice the improvement in patient outcomes. Nonetheless, it is possible that some benefit observed was partially due to general improvements in patient clinical care that occur with time. Additionally, this being a single-center experience might limit the applicability to other settings, since our hospital managed to rapidly increase the capacity for hospitalization and ventilation support, potentially improving general patient care. However, the adjustment for the differences between patient groups through propensity score and conservative approach with the use of landmark analysis were directly at minimizing the risk associated with an absence of randomization. Finally, we believe that the rate of failure observed in this study of 7.3% at 14 days in those with severe COVID-19 treated with SOC and tocilizumab/methylprednisolone might help to better define the expected rate of response and calculate the number of patients needed to include in the studies assessing various treatment options.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
